依折麦布联合瑞舒伐他汀对冠心病血脂、颈动脉粥样硬化斑块和超敏C反应蛋白的影响
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
依折麦布联合瑞舒伐他汀对冠心病血脂、颈动脉粥样硬化斑块
和超敏C反应蛋白的影响
马国强;李春晓;张勇涛;杨杰书
【期刊名称】《解放军医药杂志》
【年(卷),期】2017(029)010
【摘要】目的探讨依折麦布联合瑞舒伐他汀对冠心病患者血脂、颈动脉粥样硬化斑块和超敏C反应蛋白(hs-CRP)的影响.方法选择青岛大学附属中心医院2015年1月—2016年8月收治的冠心病102例,根据治疗方式分为观察组和对照组,每组51例.对照组采用单纯瑞舒伐他汀治疗,观察组在对照组基础上采用依折麦布治疗.比较2组治疗前后血脂、颈动脉粥样硬化斑块和hs-CRP变化及不良反应情况.结果 2组治疗1、3个月后总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)及观察组甘油三酯(TG)均较治疗前降低,且观察组低于对照组(P<0.05).2组治疗后颈动脉粥样硬化斑块和hs-CRP水平均较治疗前降低,且观察组低于对照组(P<0.05).2组不良反应总发生率比较差异无统计学意义(P>0.05).结论依折麦布联合瑞舒伐他汀治疗冠心病可有效改善患者血脂、颈动脉粥样硬化斑块及hs-CRP水平,安全性高.%Objective To investigate effects of Ezetimibe combined with Rosuvastatin on blood fat, carotid ath-erosclerotic plaques and high sensitive C-reactive protein ( hs-CRP) of patient with coronary heart disease. Methods A total of 102 patients with coronary heart disease admitted during January 2015 and August 2015 were divided into observa-tion group and control group ( n=51 for each group) according to different treatment methods. Control group was treated with simple
Rosuvastatin, while observation group was treated with Ezetimibe combined with Rosuvastatin. Changes of blood fat, carotid atherosclerotic plaques and hs-CRP before and after treatment and incidence rate of adverse reaction were compared in two groups. Results After treatment for 1 and 3 monthes, total cholesterol ( TC) and low density lipo-protein cholesterol ( LDL-C) levels in two groups and triglyceride ( TG) level in observation group were significantly lower than those before treatment, and the levels in observation group were significantly lower than those in control group ( P<0. 05). After treatment, numbers of carotid atherosclerotic plaques and hs-CRP levels were significantly decreased com-pared with those before treatment in two groups, and the values in observation group were significantly lower than those in control group (P<0. 05). There was no significantly difference in incidence rate of adverse reaction between two groups P>0. 05). Conclusion Ezetimibe combined with Rosuvastatin in treatment of patient with coronary heart disease can effectively improve blood fat, carotid atherosclerotic plaques and hs-CRP levels with high safety.
【总页数】4页(P91-94)
【作者】马国强;李春晓;张勇涛;杨杰书
【作者单位】256603 山东乳山,乳山市人民医院心血管内一科;266042 山东青岛,青岛大学附属中心医院心血管内科;266042 山东青岛,青岛大学附属中心医院心血管内科;266042 山东青岛,青岛大学附属中心医院心血管内科
【正文语种】中文
【中图分类】R541.4
【相关文献】
1.瑞舒伐他汀联合依折麦布对急性冠状动脉综合征患者血脂及超敏C反应蛋白的影响 [J], 魏鹏;吴强;付强;余涛;白洁;张倩;刘贺
2.瑞舒伐他汀钙片联合依折麦布对急性冠脉综合征患者超敏C反应蛋白及血脂的影响分析 [J], 韩凤丽
3.依折麦布联合瑞舒伐他汀对冠心病血脂、颈动脉粥样硬化斑块和超敏C反应蛋白的影响 [J], 马国强;李春晓;张勇涛;杨杰书;
4.依折麦布联合瑞舒伐他汀对老年动脉粥样硬化患者斑块及血脂的影响 [J], 廖志坚;陈玲
5.瑞舒伐他汀联合依折麦布对缺血性脑卒中患者血脂水平、颈动脉斑块稳定性的影响 [J], 张丹
因版权原因,仅展示原文概要,查看原文内容请购买。